dc.contributor.author | Spain, L | |
dc.contributor.author | Walls, G | |
dc.contributor.author | Messiou, C | |
dc.contributor.author | Turajlic, S | |
dc.contributor.author | Gore, M | |
dc.contributor.author | Larkin, J | |
dc.date.accessioned | 2017-03-24T14:30:36Z | |
dc.date.issued | 2017-01-01 | |
dc.identifier.citation | Cancer immunology, immunotherapy : CII, 2017, 66 (1), pp. 113 - 117 | |
dc.identifier.issn | 0340-7004 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/503 | |
dc.identifier.eissn | 1432-0851 | |
dc.identifier.doi | 10.1007/s00262-016-1926-2 | |
dc.description.abstract | BACKGROUND: The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance. METHODS: We present the first three, consecutive patients who received re-treatment with combination ipilimumab and nivolumab for metastatic melanoma managed at our institution. RESULTS: Rechallenge with combination ipilimumab and nivolumab in the setting of prior grade 3 toxicity with initial combination therapy is feasible, and responses are seen. We highlight the fact that grade 3 toxicity is likely to recur, but if so, can be manageable. CONCLUSIONS: Retreatment with ipi + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach. | |
dc.format | Print-Electronic | |
dc.format.extent | 113 - 117 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.subject | Humans | |
dc.subject | Melanoma | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Ipilimumab | |
dc.subject | Nivolumab | |
dc.title | Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-11-06 | |
rioxxterms.versionofrecord | 10.1007/s00262-016-1926-2 | |
rioxxterms.licenseref.startdate | 2017-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer immunology, immunotherapy : CII | |
pubs.issue | 1 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 66 | |
pubs.embargo.terms | 12 months | |
icr.researchteam | Melanoma and Kidney Cancer | |
dc.contributor.icrauthor | Spain, Lavinia | |